Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 288 drug-target rows in SSL view, for TSG = RECQL4.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab RECQL4 CTLA4 4
biospecimen collection, computed tomography, echocardiography, ipilimumab, magnetic resonance imaging, nivolumab RECQL4 CTLA4 3
nivolumab, ipilimumab RECQL4 CTLA4 3
paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin, nab-paclitaxel (paclitaxel-albumin) + carboplatin, oxaliplatin + 5-fluorouracil (5fu) + leucovorin (calcium folinate/folinic acid), durvalumab, tremelimumab, nab-paclitaxel (paclitaxel-albumin) + gemcitabine, cisplatin + 5-fluorouracil (5fu) RECQL4 CTLA4 3
alvocidib, paclitaxel RECQL4 CDK9 2
bms-986207, nivolumab, ipilimumab RECQL4 CTLA4 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel RECQL4 CTLA4 2
durvalumab, tremelimumab, sbrt RECQL4 CTLA4 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study RECQL4 HDAC3 2
ipilimumab RECQL4 CTLA4 2
ly3022855, durvalumab, tremelimumab RECQL4 CTLA4 2
pembrolizumab, guadecitabine, mocetinostat RECQL4 HDAC3 2
pharmacological study, romidepsin RECQL4 ABCC1 2
pharmacological study, romidepsin RECQL4 HDAC4 2
selumetinib, medi4736, tremelimumab RECQL4 CTLA4 2
stereotactic body radiotherapy, ipilimumab, nivolumab, pembrolizumab or atezolizumab RECQL4 CTLA4 2
trabectedin, ipilimumab, nivolumab RECQL4 CTLA4 2
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat RECQL4 HDAC3 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat RECQL4 HDAC3 1
aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim RECQL4 IL2RB 1
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation RECQL4 IL2RB 1
aldesleukin, autologous tumor cell vaccine, muromonab-cd3, sargramostim, therapeutic autologous lymphocytes, surgical procedure, radiation therapy RECQL4 IL2RB 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes RECQL4 IL2RB 1
aldesleukin, muromonab-cd3, therapeutic tumor infiltrating lymphocytes, conventional surgery RECQL4 IL2RB 1
aldesleukin, therapeutic autologous lymphocytes, adjuvant therapy, conventional surgery RECQL4 IL2RB 1
aldesleukin, therapeutic autologous lymphocytes, zoledronic acid RECQL4 IL2RB 1
alvocidib, docetaxel RECQL4 CDK9 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis RECQL4 CDK9 1
anakinra RECQL4 IL1R1 1
anetumab ravtansine, biopsy, biospecimen collection, gemcitabine hydrochloride, ipilimumab, nivolumab RECQL4 CTLA4 1
anti-sema4d monoclonal antibody vx15/2503, ipilimumab, nivolumab, surgery RECQL4 CTLA4 1
au-007, aldesleukin, avelumab RECQL4 IL2RB 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab RECQL4 HDAC3 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab RECQL4 DNMT1 1
bevacizumab, temozolomide, vorinostat RECQL4 HDAC3 1
cabozantinib, durvalumab, tremelimumab RECQL4 CTLA4 1
capecitabine, vorinostat, radiotherapy, surgery to remove tumor RECQL4 HDAC3 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin RECQL4 TP53 1
chemotherapy, suramin RECQL4 F2 1
chlorpromazine, temozolomide, radiation therapy RECQL4 ADRA1B 1
cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab RECQL4 CTLA4 1
contrast-enhanced magnetic resonance imaging, ipilimumab, nivolumab, novottf-100a device, quality-of-life assessment, questionnaire administration, radiation therapy, temozolomide RECQL4 CTLA4 1
cyclophosphamide, fludarabine, aldesleukin, anti-hcd70 car transduced pbl RECQL4 IL2RB 1
cyclophosphamide, nivolumab, ipilimumab, gvax pancreas vaccine, crs-207, crs-207 RECQL4 CTLA4 1
dabigatran etexilate, warfarin RECQL4 F2 1
dalteparin, gemcitabine hydrochloride, diagnostic laboratory biomarker analysis RECQL4 SERPINC1 1
dalteparin, radiation therapy RECQL4 SERPINC1 1
decitabine, gemcitabine RECQL4 DNMT1 1
disulfiram, copper, alkylating agents RECQL4 SERPINC1 1
disulfiram, copper, alkylating agents RECQL4 SERPIND1 1
disulfiram, copper, alkylating agents RECQL4 F2 1
durvalumab 50 mg/ml, tremelimumab RECQL4 CTLA4 1
durvalumab, carboplatin auc 2/paclitaxel, external beam radiation (ebrt), esophagogastrectomy, tremelimumab RECQL4 CTLA4 1
durvalumab, doxorubicin-eluting beads, tace, bevacizumab, tremelimumab RECQL4 CTLA4 1
durvalumab, gemcitabine, nab paclitaxel, tremelimumab, propranolol, cisplatin RECQL4 CTLA4 1
durvalumab, laboratory biomarker analysis, surgical procedure, tremelimumab RECQL4 CTLA4 1
durvalumab, tremelimumab, folfiri protocol RECQL4 CTLA4 1
durvalumab, tremelimumab, yttrium-90 radioembolisation RECQL4 CTLA4 1
e. coli cd-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis RECQL4 DNMT1 1
e7 tcr cells, aldesleukin, fludarabine, cyclophosphamide RECQL4 IL2RB 1
endoscopic variceal ligation, carvedilol RECQL4 ADRA1B 1
epidermal growth factor receptor(egfrv)iii chimeric antigen receptor (car) transduced pbl, aldesleukin, fludarabine, cyclophosphamide RECQL4 IL2RB 1
eras-007, encorafenib, cetuximab, palbociclib RECQL4 STK36 1
ethanol, enoxaparin RECQL4 SERPINC1 1
ethanol, enoxaparin RECQL4 F2 1
flucytosine, polymerase chain reaction, immunohistochemistry staining method, gene therapy, pharmacological study, 3-tesla magnetic resonance imaging, laboratory biomarker analysis, therapeutic conventional surgery, e. coli cd-expressing genetically modified neural stem cells RECQL4 DNMT1 1
fluorouracil, intensity-modulated radiation therapy, ipilimumab, nivolumab, oxaliplatin, therapeutic conventional surgery RECQL4 CTLA4 1
ft-2102, azacitidine, nivolumab, gemcitabine and cisplatin RECQL4 DNMT1 1
gemcitabine, nab-paclitaxel, durvalumab, tremelimumab RECQL4 CTLA4 1
gemcitabine, nab-paclitaxel, nivolumab, ipilimumab, sbrt RECQL4 CTLA4 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff RECQL4 HDAC3 1
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells, ipilimumab, nivolumab, quality-of-life assessment, questionnaire administration RECQL4 CTLA4 1
incagn01876, nivolumab, ipilimumab RECQL4 CTLA4 1
incagn01949, nivolumab, ipilimumab RECQL4 CTLA4 1
ipilimumab, best supportive care (bsc) RECQL4 CTLA4 1
ipilimumab, gemcitabine hydrochloride, laboratory biomarker analysis RECQL4 CTLA4 1
ipilimumab, laboratory biomarker analysis, nivolumab, temozolomide RECQL4 CTLA4 1
ipilimumab, pancreatic cancer vaccine RECQL4 CTLA4 1
ipilimumab, vaccine, folfirinox RECQL4 CTLA4 1
kras peptide vaccine, nivolumab, ipilimumab RECQL4 CTLA4 1
kras tcr-transduced pbl, aldesleukin, fludarabine, cyclophosphamide RECQL4 IL2RB 1
laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat RECQL4 HDAC3 1
mebendazole RECQL4 TUBA1A 1
mebendazole, vincristine, carboplatin, temozolomide, bevacizumab, irinotecan RECQL4 TUBA1A 1
medi4736 + tremelimumab, medi4736 + tremelimumab, medi4736, tremelimumab, medi4736+tremelimumab, medi4736 + tremelimumab RECQL4 CTLA4 1
medi4736, tremelimumab RECQL4 CTLA4 1
nab-paclitaxel, gemcitabine, cisplatin, anakinra RECQL4 IL1R1 1
nivolumab, bevacizumab, ipilimumab RECQL4 CTLA4 1
nivolumab, ipilimumab, cisplatin, fluorouracil RECQL4 CTLA4 1
nivolumab, ipilimumab, cobimetinib RECQL4 CTLA4 1
nivolumab, ipilimumab, oxaliplatin, capecitabine, leucovorin, fluorouracil RECQL4 CTLA4 1
nivolumab, ipilimumab, radiation therapy (rt) RECQL4 CTLA4 1
nivolumab, ipilimumab, relatlimab, daratumumab RECQL4 CTLA4 1
nivolumab, ipilimumab, stereotactic body radiation therapy, low dose irradiation RECQL4 CTLA4 1
nivolumab, nivolumab, ipilimumab RECQL4 CTLA4 1
nivolumab-placebo, nivolumab, ipilimumab-placebo, ipilimumab, surgery RECQL4 CTLA4 1
omeprazole, melatonin RECQL4 MTNR1A 1
patupilone RECQL4 TUBA1A 1
pegph20, nab-paclitaxel, gemcitabine, dexamethasone, enoxaparin RECQL4 SERPINC1 1
pegph20, nab-paclitaxel, gemcitabine, dexamethasone, enoxaparin RECQL4 F2 1
pembrolizumab, azacitidine RECQL4 DNMT1 1
pembrolizumab, vorinostat, temozolomide, radiotherapy RECQL4 HDAC3 1
pep-3-klh conjugate vaccine, daclizumab, temozolomide, placebo, pep-3-klh RECQL4 IL2RB 1
proflavine RECQL4 F2 1
proflavine, mobile, augmented high resolution microendoscope RECQL4 F2 1
radiation, cisplatin, durvalumab, tremelimumab RECQL4 CTLA4 1
ramipril RECQL4 BDKRB1 1
recombinant interferon alfa-2b, cisplatin, sodium stibogluconate, dacarbazine, vinblastine RECQL4 TUBA1A 1
rna-loaded dendritic cell vaccine, basiliximab RECQL4 IL2RB 1
romidepsin RECQL4 ABCC1 1
romidepsin RECQL4 HDAC4 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule RECQL4 ABCC1 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule RECQL4 HDAC4 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule RECQL4 DNMT1 1
selinexor, temozolomide, generic radiation therapy (rt), selective serotonin receptor (5-ht3) antagonists, olanzapine, salt tablets, anti-diarrheal RECQL4 ADRA1B 1
suramin, radiation therapy RECQL4 F2 1
tadalafil, pembrolizumab, ipilimumab, crs-207 RECQL4 CTLA4 1
temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin RECQL4 BDKRB1 1
temozolomide, conformal brain radiation therapy, nivolumab, ipilimumab, bevacizumab, 5-day temozolomide, 5-day temozolomide, lomustine, nivolumab monotherapy RECQL4 CTLA4 1
tetrahydrouridine, decitabine RECQL4 DNMT1 1
therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis, positron emission tomography RECQL4 IL2RB 1
ticagrelor, dabigatran etexilate, aspirin, clopidogrel RECQL4 F2 1
tinzaparin, tinzaparin RECQL4 SERPINC1 1
trametinib, vinblastine RECQL4 TUBA1A 1
unpulsed dcs, td, human cmv pp65-lamp mrna-pulsed autologous dcs, 111in-labeled dcs, temozolomide, saline, basiliximab RECQL4 IL2RB 1
vorinostat, bevacizumab RECQL4 HDAC3 1
vorinostat, bevacizumab, irinotecan RECQL4 HDAC3 1
vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis RECQL4 HDAC3 1
vorinostat, conventional surgery RECQL4 HDAC3 1
vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study RECQL4 HDAC3 1
vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration RECQL4 HDAC3 1
vorinostat, therapeutic conventional surgery, bortezomib RECQL4 HDAC3 1
young til, aldesleukin, cyclophosphamide, fludarabine, pembrolizumab (keytruda) RECQL4 IL2RB 1
abciximab RECQL4 ITGA2B 6
afatinib dimaleate RECQL4 EGFR 6
agomelatine RECQL4 MTNR1A 6
alfuzosin RECQL4 ADRA1B 6
alfuzosin hydrochloride RECQL4 ADRA1B 6
antithrombin alfa RECQL4 F2 6
ardeparin sodium RECQL4 SERPINC1 6
argatroban RECQL4 F2 6
azacitidine RECQL4 DNMT1 6
belantamab mafodotin RECQL4 TUBA1A 6
belinostat RECQL4 HDAC3 6
belinostat RECQL4 HDAC4 6
belinostat RECQL4 HDAC5 6
bivalirudin RECQL4 F2 6
bortezomib RECQL4 PSMD1 6
carfilzomib RECQL4 PSMD1 6
carfilzomib RECQL4 PSMA2 6
carvedilol RECQL4 ADRA1B 6
carvedilol phosphate RECQL4 ADRA1B 6
cetuximab RECQL4 EGFR 6
dabigatran etexilate RECQL4 F2 6
dabigatran etexilate mesylate RECQL4 F2 6
dalteparin sodium RECQL4 SERPINC1 6
decitabine RECQL4 DNMT1 6
desirudin RECQL4 F2 6
dextrothyroxine RECQL4 THRB 6
dextrothyroxine sodium RECQL4 THRB 6
dipivefrin RECQL4 ADRA1B 6
dipivefrin hydrochloride RECQL4 ADRA1B 6
docetaxel RECQL4 TUBA1A 6
doxazosin RECQL4 ADRA1B 6
doxazosin mesylate RECQL4 ADRA1B 6
doxycycline RECQL4 MMP1 6
doxycycline calcium RECQL4 MMP1 6
doxycycline hyclate RECQL4 MMP1 6
enoxaparin sodium RECQL4 SERPINC1 6
ephedrine RECQL4 ADRA1B 6
ephedrine hydrochloride RECQL4 ADRA1B 6
ephedrine sulfate RECQL4 ADRA1B 6
epinephrine RECQL4 ADRA1B 6
epinephrine bitartrate RECQL4 ADRA1B 6
eptifibatide RECQL4 ITGA2B 6
ergoloid RECQL4 ADRA1B 6
ergoloid mesylates RECQL4 ADRA1B 6
eribulin RECQL4 TUBA1A 6
eribulin mesylate RECQL4 TUBA1A 6
erlotinib hydrochloride RECQL4 EGFR 6
fondaparinux RECQL4 SERPINC1 6
fondaparinux sodium RECQL4 SERPINC1 6
heparin calcium RECQL4 SERPINC1 6
heparin sodium RECQL4 SERPINC1 6
hydroxyamphetamine RECQL4 ADRA1B 6
hydroxyamphetamine hydrobromide RECQL4 ADRA1B 6
icatibant acetate RECQL4 BDKRB2 6
isoxsuprine RECQL4 ADRA1B 6
isoxsuprine hydrochloride RECQL4 ADRA1B 6
ixazomib RECQL4 PSMD1 6
ixazomib RECQL4 PSMA2 6
ixazomib citrate RECQL4 PSMD1 6
ixazomib citrate RECQL4 PSMA2 6
labetalol RECQL4 ADRA1B 6
labetalol hydrochloride RECQL4 ADRA1B 6
lapatinib RECQL4 EGFR 6
lapatinib ditosylate RECQL4 EGFR 6
lepirudin RECQL4 F2 6
levonordefrin RECQL4 ADRA1B 6
levothyroxine RECQL4 THRB 6
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.